DICE Therapeutics is a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates for chronic diseases in immunology and other therapeutic areas
DICE Therapeutics is a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to develop novel oral therapeutic candidates for chronic diseases in immunology and other therapeutic areas. The company aims to create oral small molecule therapeutics that can modulate protein-protein interactions, targeting well-validated biologic targets. Their lead candidate is S011806, an oral antagonist of interleukin-17 (IL-17), with additional candidates targeting integrins for other